Finance

Lists
ENGN:NASDAQ
enGene Therapeutics Inc
1,70 $
-1,73%
(-0,030) 1D
12 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
1,73 $
High
1,74 $
Low
1,69 $
Mkt. cap
113,93 млн
Avg. vol.
726,56 м.
Volume
462,72 м.
52-wk high
12,25 $
52-wk low
1,40 $
EPS
-2,08 $
Beta
-0,29
Shares outstanding
67,02 млн
No. of employees
82
Open
1,73 $
High
1,74 $
Low
1,69 $
Mkt. cap
113,93 млн
Avg. vol.
726,56 м.
Volume
462,72 м.
52-wk high
12,25 $
52-wk low
1,40 $
EPS
-2,08 $
Beta
-0,29
Shares outstanding
67,02 млн
No. of employees
82
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
Sector-
Websiteengene.com
Analyst ratings
Based on 5 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
1
Hold
3
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current 1,70 $
4,00 $ (+135,29%)
Average
2,50 $ (+47,06%)
Lowest
2,00 $ (+17,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Hold
Maintained
2,00 $
+17,6%
10/02/2026
David Dai
UBS
Hold
Reiterated
2,00 $
+17,6%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
2,00 $
+17,6%
09/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
4,00 $
+135,3%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
4,00 $
+135,3%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
4,00 $
+135,3%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
21,50 $
+1 164,7%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
21,50 $
+1 164,7%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
21,50 $
+1 164,7%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
28,00 $
+1 547,1%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қаз.
2026 ж. қаң.
2026 ж. сәу.
2026 ж. шіл.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31,72 млн
22,26 млн
22,20 млн
20,09 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,76 млн
8,93 млн
9,77 млн
13,92 млн
Operating expense
39,48 млн
31,18 млн
31,97 млн
34,01 млн
Total operating expenses
39,48 млн
31,18 млн
31,97 млн
34,01 млн
Operating income
-39,48 млн
-31,18 млн
-31,97 млн
-34,01 млн
Other non operating income
448,00 м.
-
-
-
EBT including unusual items
-38,38 млн
-29,75 млн
-30,23 млн
-32,50 млн
EBT excluding unusual items
-38,38 млн
-29,26 млн
-30,23 млн
-32,50 млн
Income tax expense
-497,00 м.
-
-
-
Effective tax rate
1,29%
-
-
-
Other operating expenses
-
-
-
-
Net income
-37,88 млн
-29,75 млн
-30,23 млн
-32,50 млн
Net profit margin
-
-
-
-
Earnings per share
-0,73
-0,44
-0,43
-0,47
Interest and investment income
1,98 млн
2,74 млн
2,66 млн
2,40 млн
Interest expense
-750,00 м.
-732,00 м.
-745,00 м.
-843,00 м.
Net interest expenses
1,22 млн
2,01 млн
1,92 млн
1,56 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,31 млн
-31,00 млн
-31,79 млн
-33,84 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары